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Neurodegenerative diseases are going to increase as the life expectancy is getting longer. The management of neurodegenerative
diseases such as Alzheimer’s disease (AD) and other dementias, Parkinson’s disease (PD) and PD related disorders, motor neuron
diseases (MND),Huntington’s disease (HD), spinocerebellar ataxia (SCA), and spinalmuscular atrophy (SMA), ismainly addressed
tomotor and cognitive impairment, with special care to vital functions as breathing and feeding.Many of these patients complain of
painful symptoms though their origin is variable, and their presence is frequently not considered in the treatment guidelines, leaving
their management to the decision of the clinicians alone. However, studies focusing on pain frequency in such disorders suggest a
high prevalence of pain in selected populations from 38 to 75% in AD, 40% to 86% in PD, and 19 to 85% in MND.The methods of
pain assessment vary between studies so the type of pain has been rarely reported. However, a prevalent nonneuropathic origin of
pain emerged for MND and PD. In AD, no data on pain features are available. No controlled therapeutic trials and guidelines are
currently available. Given the relevance of pain in neurodegenerative disorders, the comprehensive understanding of mechanisms
and predisposing factors, the application and validation of specific scales, and new specific therapeutic trials are needed.
1. Introduction
Neurodegenerative diseases are going to increase in parallel
to the lengthening of survival. The most common of them
become more prevalent with age being accompanied by pro-
gressive motor and cognitive impairment. The management
of neurodegenerative diseases as Alzheimer’s disease (AD)
and other dementias, Parkinson’s disease (PD) and PD related
disorders, motor neuron diseases (MND), Huntington’s dis-
ease (HD), spinocerebellar ataxia (SCA), and spinalmuscular
atrophy (SMA), is mainly addressed to motor and cognitive
impairment with special care to the vital functions as breath-
ing and feeding. Many of these patients complain of painful
symptoms though their origin is variable, and their presence
is frequently not considered in the treatment guidelines,
leaving their management to the decision of the clinicians
alone. In some neurodegenerative diseases as Parkinson’s
disease, pain has recently been recognized as a frequent and
invalidating symptom [1]. In general, pain treatment should
mainly be based on its pathophysiological mechanisms.
According to the International Association for the Study of
Pain (IASP), pain is an unpleasant sensory and emotional
experience associated with actual or potential tissue damage
or described in terms of such damage [2]. Most pain syn-
dromes are neuropathic or nociceptive in their origin. While
central and peripheral neuropathic pain are caused by a lesion
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or disease of the central or peripheral somatosensory nervous
system, respectively, the nociceptive pain arises from actual
or threatened damage to nonneural tissue and is due to the
activation of nociceptors [3].Thus, nociceptive pain occurs in
patients with a normally functioning somatosensory nervous
system [3]. Neurodegeneration may specifically involve the
somatosensory system, thus making a neuropathic origin of
pain very likely, or it may affect cortical and subcortical struc-
tures involved in pain modulation. Motor impairment with
muscular tone abnormalities and reduced active mobility
may cause osteoarticular problems with local inflammation
and nociceptive pain. Inmany neurodegenerative conditions,
the origin of pain is complex, often multifactorial and hardly
classifiable as merely neuropathic or nociceptive. In addition,
there are few evidences on frequency and characteristics
of pain symptoms in neurodegenerative disorders and on
their impact on the disease outcome. An IASP task force
[4] has revised the clinical and instrumental assessment of
chronic pain as well as its therapeutic management so a
systematic application of these guidelines to chronic pain in
neurodegenerative diseases should be within reach. However,
pain assessment may be hampered by the impairment of cog-
nitive and motor performances so special recommendation
should be provided upon approaching this important aspect
of neurodegenerative diseases.
The present review focuses on chronic pain in main neu-
rodegenerative diseases addressing the current knowledge
about pain frequency and clinical features, clinical and instru-
mental assessment, possible pathophysiological mechanisms,
and the current evidence on pain therapeutic management.
Also themain limitations of the present studies and the future
research direction and perspectives are considered.
We also dedicated a section to rare neurodegenerative
conditions where pain was not extensively assessed.
This was a narrative review based on PubMed search by
the following key words: pain, pain frequency, pain features,
pain treatment and Alzheimer disease, Parkinson’s disease,
extrapyramidal disorders, motor neuron disease, and spino-
cerebellar ataxia. There was no time limit for the research,
starting form the first date reported by PubMed.
2. Alzheimer Disease and Other Dementias
Dementia refers to a broad category of brain neurodegen-
erative diseases that are accompanied by loss of ability in
memory function, attention, executive function, orientation,
language, and other cognitive domains as well as by changes
in mood and behavior, which increase across the course of
dementia. There are an estimated 35 million people with
dementia in the world. The most common type of dementia
is Alzheimer’s disease. Other forms of dementia are vascular
dementia, frontotemporal dementia, and Lewy body demen-
tia. Given that the prevalence rate of dementia is tightly
linked to ageing, the increase of ageing population is themain
reason for the predicted substantial growth in the number of
people affected by dementia. Not only do prevalence rates of
dementia increase with age, but also the prevalence rates of
pain are strongly linked to ageing [5]. Given that both the
prevalence rates of dementia and pain increase with age, it
appears that pain is highly common among people suffering
from dementia. The difficulty is, however, that patients with
dementia (particularly those in the advanced stages of the
disease) are often unable to use self-report to communicate
their suffering, and thus their pain is often overlooked and
remains untreated [6].
2.1. Pain Frequency and Clinical Features. Due to their
advanced age, individuals with dementia often suffer from
multiplemorbidities associated with pain. However, the exact
pain prevalence in dementia is unknown due to the lack
of self-report in this patient group as mentioned previously.
Studies using observational tools to assess pain indicate that
about 50% of patients with dementia living in nursing homes
are suffering from pain [13, 28].This is in line with prevalence
rates reported about nursing home patients, independently
of their cognitive status. Yet, the prevalence of pain among
patients with dementia is associated with the severity of the
condition. In fact, between 45% and 83% of the patients living
in nursing homes experience acute or chronic pain [29].
Most of these patients (about 94%) were reported to suffer
from persistent pain (3–6 months or more). The causes of
pain among patients with dementia living in nursing homes
include but are not restricted to genitourinary infections,
pathologies in the musculoskeletal system [30], pressure
ulcers [31], and skin diseases, with the latter of which found in
95%of the patients and described as one of themost prevalent
health problems in this population [32].
Several studies have estimated the prevalence rates of pain
among patients with dementia who are living at home.These
prevalence rates are listed in Table 1 [7–13]. What appears
evident is that the rates vary across studies, depending
on whether they are based on the self-report or on the
caregivers’ report. Overall, at least 50% of the community
dwelling patients with dementia seem to be suffering from
pain. Considering the aforementioned studies, pain is highly
prevalent among patients with dementia whether living in
nursing homes or living at home, and thus its management
required careful assessment and monitoring.
2.2. Clinical and Instrumental Assessment. Given the high
prevalence of pain in the elderly, proper assessment of pain
by observers such as health care professionals or family
members is required for successful pain treatment. Due to
the subjective and complex nature of the pain experience,
assessing patients’ pain is often a challenge. The more severe
the cognitive impairment is and hence the more severe the
loss of self-report is, the greater the challenge is [33]. In
such instances, caregivers should rely less on self-report and
more on behavioral indicators of pain. Facial expressions
in particular seem to provide a valid indication of the
patients’ pain. Patients with dementia display the same types
of facial movements in response to pain as cognitively
intact individuals [34, 35]. Thus, the pain-peculiarity of their
facial expression is not reduced. This finding implies that
facial expressions of pain have the potential to serve as an
alternative pain indicator in patients with dementia. Other
means to indirectly assess pain are various behavior rating
scales (for comprehensive reviews, see, e.g., Herr et al. [36]
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Table 1: Summary of the studies on the prevalence of pain among patients with dementia living at home or in nursing homes. Features and
location of pain were not available.
Study design Number of patients andcontrols Assessment method Frequency of pain
Barry et al. [7] Observational Patients: 75Controls: 0 Interview with patients and caregivers
Daily pain
Patients’ report: 57%
Caregivers’ report: 71%
Barry et al. [8] Observational Patients: 42Controls: 0 Interview with patients, nurses, and relatives
Daily pain
Patients’ report: 38%
Nurses’ report: 69%
Relatives’ report: 75%
Hunt et al. [9] Observational Patients: 802Controls: 802 Interview with patients
Bothersome pain
Patients’ report: 64%
Controls’ report: 55%
Werner et al. [10] Observational Patients: 141Controls: 55 Category rating scale
Pain is experienced
Patients’ report: 21%
Patients’ and Caregivers’
report: 46%
Controls’ report: 48.1
Ma¨ntyselka¨ et al. [11] Observational Patients: 75Controls: 446 Interview with the patients
Any pain
Patients’ report: 43%
Controls’ report: 69%
Shega et al. [12] Observational Patients: 150Controls: 0 Interview with patients and caregivers
Pain right now
Patients’ report: 32%
Caregivers’ report: 52%
Zwakhalen et al. [13] Observational Patients: 117Controls: 0 Observational pain scale
Experience of pain to some
extent
Nurses’ observations: 47%
and Zwakhalen et al. [13]). However, the validation process
of these scales has just started. Although the first results
are promising, future studies are needed to define which
items are able to discriminate between pain behavior and
behaviors related to other aspects of unmet needs in patients
with dementia.Within a European initiative (COSTTD1005),
researchers across Europe have started to investigate which
behavioral items can indeed validly indicate the presence of
pain in patients with different types of cognitive impairment.
The process is still ongoing [37] but will hopefully be
completed within the next 1-2 years.
2.3. Possible Pathophysiological Mechanisms. Only a few
experimental studies have tried to investigate how dementia
affects the processing of nociceptive information with most
studies focusing on patients with Alzheimer’s disease (for a
comprehensive review, see Defrin et al. [38]). Alarmingly, the
majority of the experimental findings seem to suggest that the
processing and the experience of pain are not diminished in
patients with mild-to-moderate forms of dementia. On the
contrary, the pain experience might even be enhanced. It has
been reported that patientswith dementia respond to noxious
stimulation with more enhanced facial responses [34, 35]
and pain withdrawal reflexes [35] compared with cognitively
intact peers. Functional magnetic resonance imaging (fMRI)
studies showed that brain activity in response to noxious
stimulation is preserved and even elevated in patients with
mild forms of Alzheimer’s disease [39, 40] corroborating
findings based on facial and reflexive expressions. Using
evoked related potentials (ERPs), one study found no dif-
ference in peak amplitude between patients and controls
[41] and one study failed to induce pain-evoked potentials
in the subgroup of patients with severe dementia [42].
The widespread brain damage occurring in the course of
dementia might possibly affect descending pain modula-
tion pathways most strongly in mild-to-moderate stages of
dementia, which in turn lead to reduced inhibitory control
over the pain system and increased pain processing. In later
stages of dementia, the ascending pain pathways might be
affected more severely, resulting in reduced pain processing.
However, this is only speculative since research on patients at
severe stages of dementia is lacking.
2.4. Current Evidence on Pain Therapeutic Management.
Recent reviews on painmanagement in patients with demen-
tia point to a severe lack of effective assessment and treatment
in different clinical settings and to the conclusion that
even today patients with dementia are still undertreated
for pain compared with nondemented elderly individu-
als [43, 44]. However, this seems to be slowly changing.
Two studies from Scandinavia [45, 46] found that patients
with dementia received even more analgesic drugs (mostly
paracetamol) compared with those without dementia. The
increased dosage was administered even though the patients
reported pain less frequently, and the prevalence of the pain
related diagnoses was similar comparedwith persons without
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dementia. Beyond being very promising, these results clearly
suggest that the research findings of the last decades—
which reported an undertreatment of pain in dementia—
have already impacted the clinical practice and have led to an
intensification of painmanagement in this frail patient group.
2.5. Main Limitations of the Present Studies and Future
Directions. In the last two decades, much effort has been
invested to better understand how dementia affects the
pain processing as well as its assessment. Up to now, an
impressive number of pain behavior rating scales have been
developed trying to assess pain based on nonverbal behavior.
However, the validity, usability, and feasibility of these scales
are still unsatisfactory, and they are not often used in the
clinical practice. Moreover, dementia is a very broad concept
that includes not only various types of neurodegenerative
processes affecting different brain areas but also different
degrees of cognitive decline. Most studies do not differentiate
between different types or stages of dementia. Moreover,
research investigating patients with dementia at the last
stage of the disease is still mostly lacking, and, therefore,
we do not know how pain processing might be altered in
these very fragile patients. Moreover, it is an alarming fact
that patients with dementia are still excluded from high
quality randomized controlled trials of pain treatment. This
underlines the comprehensive need of research as well as
excellent implementation concepts for pain assessment and
pain treatment in elderly individuals with dementia.
3. Parkinson’s Disease and Other
Extrapyramidal Disorders
Patients with Parkinson’s disease (PD) often experience pain.
By now, pain is commonly accepted to represent one of the
PD nonmotor symptoms having a remarkable impact on
the PD patients’ quality of life. While pain was considered
initially as an epiphenomenon of the motor impairment
characteristic of the disease, the attention toward this symp-
tom has increased in the last ten years. Two main elements
led clinical and research efforts to understand the pain
mechanisms in PD: (1) the higher prevalence of pain in PD
patients compared to that in the healthy elderly subjects and
(2) the involvement of nondystonic body parts, which means
that pain is possibly linked to the intrinsic pathophysiological
mechanisms of the disease.
3.1. Pain Frequency and Clinical Features. Pain in PD is
commonly assessed according to Ford’s scheme [47]. Five
different types of pain can be recognized: (1) musculoskeletal,
(2) radicular-neuropathic, (3) dystonic, (4) central neuro-
pathic, and (5) akathisia pain. Whether the classical distinc-
tion between the nociceptive and the neuropathic pain is
used or not, most Parkinsonian patients refer a nociceptive
pain, which can be mainly musculoskeletal and visceral.
Musculoskeletal pain derives from abnormal postures of the
dystonic body parts, rigidity, and akinesia. Visceral pain
is often the consequence of the abnormal function of the
vegetative nervous system typical of the disease [48]. In
PD, an example of neuropathic pain is represented caused
by nerve root irritation following the abnormal posture
and motor activity of the Parkinsonian patients. However,
most papers on PD pain consider also a far less defined
“central neuropathic” pain. This is poorly localized and often
described as “boring,” “constant,” and “burning” [49]. The
classification of this “central pain” is questionable according
to the commonly accepted definition of neuropathic pain as
being due to a lesion or a disease of the somatosensory system
[3]. Although a clear sensory deficit cannot be demonstrated
in PD patients with central pain, there are evidences linking
this kind of pain to basal ganglia dysfunctions [50] and
abnormal nociception [51].
Although several studies investigated the epidemiologic
characteristic of pain in PD, the exact prevalence of this
disabling symptom is not definitely known, ranging from30%
to 80% [49]. A recent meta-analysis [52] identified 8 studies
which met the criteria of the Quality Assessment of Diagnos-
tic Accuracy Studies (QUADAS) tool. In these studies, the
average prevalence of pain was 67.6%, ranging from 40% to
85%. As for the location, the pain was prevalently referred to
the lower limbs (47.2%) while it involved less frequently the
back (14.3%), the upper limbs (13.4%), and the neck/shoulder
region (12.4%).Themost frequently reported type of painwas
the musculoskeletal one (46%) followed by dystonic (19.6%)
and radicular (9.1%) pain. Central neuropathic pain was
found in 5.6% of PD patients. Interestingly, the only available
community study performed in Norway by Beiske et al. [1]
reports the highest prevalence of pain in PD as compared to
healthy subjects (83% versus 30%). Valkovic et al. [16] have
very recently investigated themodifications in the prevalence
of pain during the disease progression. Interestingly, all the
4 Parkinson-related types of pain considered in this study
(musculoskeletal, dystonic, radicular, and neuropathic) were
more prevalent in the advanced stages of PD confirming their
strict relationship with the disease.
It should be mentioned that a couple of studies failed in
showing a higher prevalence of pain in PD patients compared
to that in healthy subjects [53, 54]. In these studies, however,
the prevalence of pain was very low in PD patients as
compared to other studies or high in healthy subjects thus
suggesting an ascertainment bias [15] (Table 2).
3.2. Clinical and Instrumental Assessment. Though pain is
very prevalent in PD, inmost studies rating scales not specific
for this disease were used. Only a very recent multicenter
study published the first PD pain specific scale [55]. King’s
Parkinson’s Disease Pain Scale (KPPS) is an interview-based
scale used to explore the frequency, intensity, and location
of each type of PD pain. Moreover, it also rates the pain
modifications associated with motor fluctuations in PD.
3.3. Possible Pathophysiological Mechanisms. Although the
epidemiological data support the linkage between at least
certain types of pain and the biological background of the
disease, the pathophysiological mechanisms of pain in PD
patients are far from being ascertained. According to the
current idea, abnormal nociceptivemechanisms,which could
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Table 2: Summary of studies on the prevalence and features of pain among patients with Parkinson’s disease.
Study design
Number of
patients and
controls
Assessment methods Frequency of pain Feature and location of pain
Ne`gre-Page`s et al. [14] Observational 450 Visual analogue scale 278 patients (61.8%) PD related (167 patients)Other types (111 patients)
Defazio et al. [15] Case control 402 Visual analogue scale 281 patients (69.9%) and199 controls (62.8%)
Nondystonic (267 patients)
Dystonic and nondystonic
(14 patients)
Beiske et al. [1] Observational 176 Structured interview(SF-36) 147 patients (83%)
Musculoskeletal (103
patients)
Dystonic (59 patients)
Radicular (0 patients)
Central (15 patients)
Valkovic et al. [16] Observational 100
Brief Pain Inventory
Leeds assessment of
neuropathic symptoms
and signs
76 patients (76%)
Musculoskeletal (41%)
Radicular (27%)
Central (22%)
Dystonic (17%)
Others (31%)
Tinazzi et al. [17] Observational 117 Visual analogue scale 47 patients (40%)
Dystonic (19 patients)
Musculoskeletal (22
patients)
Radicular (4 patients)
Central (2 patients)
predispose patients to develop spontaneous pain, could be
found in PD.This is suggested by psychophysical and neuro-
physiologic studies in PD patients without pain [15]. Reduced
thresholds to different pain modalities were found in PD
patients without pain compared with the control subjects
[17, 51, 56–63]. Moreover, the laser evoked potential (LEP)
amplitude assessing the pain matrix function was reduced in
the pain-free PD patients [51] even in the early stages of the
disease [58]. As for the role of dopamine in the development
of PD pain, the available results are not univocal. Indeed,
elements suggesting dopamine importance are represented
by the more frequent involvement of the affected side in
hemi-Parkinson and the pain modifications according to the
PD motor fluctuations [14, 64]. However, the psychophysical
and neurophysiologic abnormalities shown in PD patients
cannot generally recover after dopamine administration [65].
Monoaminergic systems different from the dopaminergic
one could be involved in the pathophysiology of pain in PD.
Finally, it is worth mentioning that a reduction of small
unmyelinated fibers was reported in PD both in the skin
biopsy [66] and in cornea [67]. However, the meaning of the
peripheral fiber reduction in the neurophysiological findings
is not clear since the last ones seem most dependent on
central nervous system modifications.
3.4. Current Evidence on Pain Therapeutic Management. No
systematic study on pain treatment in PD is currently avail-
able. However, it is conceivable that the treatment strongly
depends on the type of pain. Broen et al. [52] reviewed
3 studies, which provided some data. According to them,
37.6% of the PD patients use nonopioid analgesic while 13.5%
of them use opioids and 11.8% of them use antidepressant
and/or anticonvulsive drugs. Kass-Iliyya et al. [67] described
an analgesic effect of the deep brain stimulation (DBS)
indicated for the improvement of the motor symptoms. Eight
patients, having undergone DBS electrode implant within
the subthalamic nucleus, showed an increase of the pain
threshold when the DBS was switched on as compared to
what happened with the stimulator off.Moreover, the authors
used the positron emission tomography to investigate the
cerebral activity related to central neuropathic pain in PD
patients. It was found that the DBS could reduce the brain
activity related to pain.
3.5. Main Limitations of Present Studies and Future Direction.
In conclusion, pain in PD has become an important element
to be considered in the clinical practice since it canworsen the
general impairment of the patients. In spite of the number of
papers published in the last years, there are still some points
which should be improved. Firstly, there is still the tendency
to consider the different types of PD pain together in many
studies. This can prevent the correct identification of the
pathophysiological mechanisms and the best treatments that
are unlikely to be the same for musculoskeletal, dystonic, and
neuropathic pain. Secondly, the KPPS, which represents the
first specific PD pain scale, was published in 2016 [55] while
pain was previously assessed on the basis of the examiner’s
experience or by using some questionnaires not specific for
PD. This has surely hampered a systematic classification of
pain in PD, which represents the mandatory background for
any effective treatment.
4. Other Extrapyramidal Disorders
Although pain is often reported by patients with extrapyra-
midal disorders different from PD, there are only few studies
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dealing with pain in these conditions. Few studies dealt with
pain frequency and features in patients with Huntington’s
disease (HD). Some clinical reports suggested that pain may
not be sufficiently manifested and treated in HD patients and
that it may be an underestimated problem [68, 69]. In a study
conducted by laser evoked potentials, HD patients in the
early stages of the disease showed increased LEPs latencies,
inversely correlated with their functional capacities [70]. In
that study, only 3 out of 28 patients complained of pain
despite the presence of possible postural and muscle skeletal
abnormalities.This preliminary observationmay support the
need of more extensive multicentric observational controlled
studies.There is a consistent amount of studies indicating that
HD patients show a deficit in recognizing negative emotions
and pain of others [71, 72]. The impaired processing of
negative experiences may thus be supported by an altered
influence of basal ganglia on cortical areas devoted to the
elaboration of stimuli requesting an aversive motor response
as in the case of painful stimuli [73].The disturbed processing
of negative stimuli including painmay interfere with sensory-
motor integration [70, 74] and contribute to the global
worsening of the disease as suggested by the correlation found
between LEPs abnormalities and disability in HD patients
[70].
Some data have been collected for Cervical Dystonia
(CD), which is characterized by involuntary twisting neck
movements and abnormal head postures [75]. Early studies
reported pain in around 70% of CD patients [76, 77]. More
recently, Charles et al. [78] published epidemiological data
from 1,037 CD patients included in a USA registry (Cervical
Dystonia Patient Registry for Observation of Onabotulinum-
toxinA efficacy—CD PROBE). At baseline, that is, before
OnabotulinumtoxinA treatment, 88.9% (922/1037) of the
patients reported pain related to CD. In particular, 70.7%
(733/1037) reported moderate or severe pain intensity while
29.3% (304/1037) reported no pain or had only a mild
pain intensity. Interestingly, the patients with no/mild pain
were older than those with moderate/severe pain, while no
difference between groups was found in the onset age or the
duration of the disease. Unfortunately, no systematic pain
classification, including also a possible separation between
different types of pain (according to the model reviewed
above for pain in PD), has been performed in CD. This
contributes to the uncertainty about the pathophysiological
mechanisms subtending pain in this condition. Indeed, it is
conceivable that pain in CD can be due to the abnormal
contraction of the dystonic muscles. However, this possibility
has been challenged by the observation that botulinum toxin
treatment does not always reduce pain [79, 80]. Moreover,
pain is not always correlated with the severity of dystonia
in the neck muscles [81]. These elements could lead to
hypothesizing a susceptibility of the nociceptive system inCD
similar to that demonstrated in PD. Tinazzi et al. [82, 83]
recorded LEPs in 20 CD patients by stimulating the skin
overlying both painful and nonpainfulmuscles.They failed to
show any abnormality of the nociceptive input processing in
these patientsmaking the hypothesis of a central sensitization
of the pain matrix in CD unlikely. However, it has to be
mentioned that partially different results were obtained in
patients with nonpainful hand dystonia by using the contact
heat evoked potentials (CHEPs) [84]. Indeed, 6 out of 10
patients showed reduced amplitude of their pain related brain
responses to stimulation of the dystonic hand.
Pain was described as a common symptom also in
multiple system atrophy (MSA) [85, 86]. This finding was
confirmed by a more recent study comparing 21 MSA
patients with 65 PD patients [87]. Pain prevalence was similar
between MSA (81%) and PD (89%) patients, as well as the
scarce response of pain to dopamine administration in both
conditions. In MSA, the pathophysiology of pain could be
similar to that in PD, involving basal ganglia degeneration.
This is suggested by the results of a neurophysiological
study exploring pain processing in MSA and PD patients
by using the nociceptive withdrawal reflex (NWR) recording
[88]. MSA patients showed facilitation of a series of pain
responses as compared to healthy subjects. However, no
difference was found betweenMSA and PD patients in terms
of neurophysiological abnormalities.
The progressive supranuclear palsy (PSP) is even less
investigated than the previously reviewed conditions.The few
available data suggest that pain in PSP is far less prevalent
than that in PD [87, 88]. However, the only neurophysio-
logical study in PSP showed a lower pain threshold in PSP
patients than that in control subjects suggesting that the
apparently low prevalence of pain in this condition could be
related to the early cognitive impairment of the patients [88].
5. Motor Neuron Disease:
Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS), also known as motor
neuron disease (MND), is the most common neurode-
generative disorder of the motor system in adults. ALS is
characterized by a degeneration of primary motor neurons
in the cortex, brainstem, and spinal cord. The amyotrophy
(atrophy of muscle fibers) leads to muscular paralysis due
to loss of innervating motor neurons. The lateral sclerosis
typical of the disease refers to the upper motor neuron
axonal loss and the hardening of corticospinal tracts and the
resultant gliosis [89, 90].These changes can lead to a number
of debilitating conditions that reflect aberrant functioning
in both upper and lower motor neurons. These character-
istic features of ALS are also accompanied by a number
of secondary conditions that can be just as burdensome
as those symptoms directly associated with the disorder.
Although degeneration of motor neurons is pivotal in ALS,
it is actually considered a multisystemic disorder involving
sensory system. A spinocerebellar pathway (Clarke’s column)
taking origin in the spinal cord segments is consistently
affected in pathological studies of ALS, which may underlie
the early symptom of impaired balance often reported by
patients at diagnosis [90]. In addition, clinicians have long
noted minor sensory and autonomic involvement in patients
with ALS [91] and small fiber neuropathy was found in
skin biopsies in 79% of ALS patients [92]. The link between
ALS and frontotemporal dementia represents an extension of
ALS as a motor system disease to the frontal and temporal
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lobes, which are brain areas involved in the expression
of thought, planning, personality, and speech, all aspects
of brain function that may interfere with pain perception
[93]. The complexity of ALS pathophysiology and clinical
appearance justifies the need to manage associate symptoms
including pain.
5.1. Pain Frequency and Clinical Features. Thirty years ago,
pain was reported to occur in ASL patients [94]. In the
following years, some studies dealt with the frequency of pain
in ALS patients, though most of them were conducted in
small cohorts of patients in different stages of the disease;
in addition, the case control design was sometimes omit-
ted. In most studies, the usual classification in nociceptive
and/or neuropathic pain was not used. Ganzini et al. [18]
evaluated pain in ALS patients with direct interviews and
questionnaires to caregivers. They found that both methods
showed high representation of painful symptoms as causes of
invalidity (Table 3). A case control study on neuromuscular
diseases found that pain was present in 73% of the total
population (193 patients) with ALS patients showing the
greatest pain interference [19].Thepainwas especially located
in the back and shoulder, followed by neck, buttock and
hip(s), feet, arm(s), and hand(s) [19]. Shoulder pain was also
observed in 43 out of 193 ALS patients, independently of age,
gender, and phenotype [20].
In a case control study, Chio` et al. [21] found that ALS
patients reported pain more frequently than control subjects.
Pain was correlated with the disease stage and invalidity. In
an observational study on a small ALS series (42 patients),
19 experienced pain, which worsened the quality of life [22].
Rivera et al. [23] used the neuropathic pain scale [95] to study
pain in 63 ALS patients in different stages of the disease.
They found that about half of patients reported neuropathic
pain, which was invalidating since it was present even in the
early stages of the disease (Table 1). Pizzimenti et al. [24]
observed pain in 72% of 36 ALS patients causing depression
and a significant decline of the quality of life. More recently,
Wallace et al. [25] specified that in 81% of 41 ALS patients
complaining of pain this did not have neuropathic character-
istics. In another recent study, 78% of the examined patients
complained about pain, which interfered with the quality of
life, sleep, and mood [26]. The lack of correlation between
severity of pain and disease duration was also reported in
this latter study (Table 3). Another study applied the DN4
test for neuropathic pain scoring [96] in 92 ALS patients,
who reported only rare symptoms of neuropathic origin [27].
Summarizing, both observational and case control studies
reported a high frequency of pain in ALS patients from
around 20% in retrospective studies to 80% in case control
ones. Characteristics of pain symptoms have been collected
with different scales though the most recent studies seemed
to suggest the nonneuropathic origin of pain.
5.2. Clinical and Instrumental Assessment. As reported above,
different scales were used to assess the pain features in ALS
patients (Table 3).The short formof BPIwas generally applied
[97] while only few studies assessed the neuropathic origin of
pain with specific questionnaires as DN4 or neuropathic pain
scales [96] (Table 3). In most studies, the factors aggravating
pain, such as depression and sleep disturbances, were also
assessed.
Neurophysiological studies and in particular electromyo-
graphy and electroneurography are routinely applied for
diagnostic purposes to explore motor system in ALS patients
[98] while the employment of methods for the specific
assessment of nociceptive pathways functions was rarely
reported though it would be useful to improve the knowledge
about pain pathophysiology and its management. Contact
heat evoked potentials were used to explore noxious stimuli
conduction along the C-fibers in 60 ALS patients versus
60 controls, and no significant abnormality was found in
patients corroborating the hypothesis of an intact nociceptive
system [99]. These results were not confirmed in a CO2 laser
evoked potentials (LEPs) study conducted in 23 ALS patients
[100], who showed an increase in LEPs latencies but also
in the amplitude of the earlier latency N1 potential. This
is a contradictory result possibly explained by a probable
dysfunction of the nociceptive pathways at subcortical level
[101], coexisting with enhanced excitability of the nociceptive
cortex as a result of motor cortex degeneration. In that study,
19 patients complained about pain, which was usually of the
musculoskeletal type supporting the hypothesis that, also in
the presence of signs of nociceptive system dysfunction, pain
is an indirect consequence of motor impairment [100]. Small
fiber involvement was demonstrated by skin biopsy. Weis et
al. [92] found a significant reduction in the epidermal nerve
fiber density in the distal calf of patients with ALS, which was
recently confirmed in another study based on skin biopsy and
Quantitative Sensory Testing (QST). In this last study, only
patients with spinal onset, but not those with bulbar form,
showed an impairment of the thermal sensitivity and distal C
afferents [102]. Moreover, a sensitive axonal involvement may
be a feature of ALS subtypes.
5.3. Possible Pathophysiological Mechanisms. Clinical studies
seem to indicate the nonneuropathic origin of pain in the
majority of ALS patients though the complexity of this multi-
systemic degenerative disordermay account for a dysfunction
of the nociceptive system at both peripheral and central level.
The neuropathic components of ALS-related pain can be
present even in the early phases of the disease and worsen the
musculoskeletal pain. The presence of the nociceptive affer-
ents dysfunction in ALS is suggested by both skin biopsies
and QST especially in the spinal onset phenotype [18, 102].
In addition, the complex interaction between the motor and
sensory cortex may cause disinhibition and hyperactivation
of sensory functions in order to improve sensory-motor
integration in a situation of motor failure [103, 104]. This
could explain the increased amplitude of LEPs [100] and SEPs
[105] observed in the early stages of the disease.
5.4. Current Evidence on Pain Therapeutic Management. A
recent Cochrane review [106] reported that there is no
evidence from randomized controlled trials about the man-
agement of pain in ALS so no guidelines on this important
aspect of the disease are available for clinicians. In an
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Table 3: Summary of studies on the prevalence and features of pain among patients with amyotrophic lateral sclerosis.
Study design Number of patientsand controls Assessment methods Frequency of pain Feature and location of pain
Ganzini et al.
[18] Observational 100 patients
Interview to patients and
caregivers
19% reporting
moderate to severe
pain
Not reported
Jensen et al. [19] Observational
193 patients with
neuromuscular
disease
(30 ALS)
Neuropathic pain scale,
Brief Pain Inventory,
quality of life (SF-36)
60% of ALS
patients
“Deep,” “tiring,” “sharp,”
and “dull”
Localized in the back, leg,
shoulder, and neck (total of
patients with
neuromuscular disease)
Ho et al. [20] Retrospective 193 patients Standard medical records 23% Shoulder pain
Chio` et al. [21] Case control 160 patients Brief Pain Inventory 56.9% Pain more frequent in theextremities
Pagnini et al.
[22] Observational 40 patients
Italian Pain Questionnaire,
McGill Quality of Life
Questionnaire
51.2%
“Nagging,”
“sore,” “periodic,”
“annoying,” “exhausting,”
“enduring,”
“debilitating,” and
“worrying”
Rivera et al. [23] Observational 63 Neuropathic pain scale 50% Neuropathic pain
Pizzimenti et al.
[24] Observational 36
Neuropathic Pain Symptom
Inventory
(2 items)
71%
Localized in
scapular-humeral area and
lower limb
Wallace et al.
[25] Case control 42
Brief Pain Inventory
PainDETECT
Questionnaire
85%
Nonneuropathic:
cramping, aching, tiring,
sharp, and tender
Hanisch et al.
[26] Case control 46 Brief Pain Inventory 78% Cramps
Moisset et al.
[27] Observational 93 DN4 questionnaire 66% 9% neuropathic pain
observational study, 17 out of 36 ALS patients complain-
ing about pain received treatment with nonsteroidal anti-
inflammatory drugs, opioid, or antiepileptics with unspec-
ified results [24]. In another observational study, 63% of
91 ALS patients suffering from pain were under treatment
in most of the cases with nonsteroidal anti-inflammatory
drugs and nonopioid analgesics [21]. Cramps are currently
treated by carbamazepine or phenytoin [107]. In a hospice
study, where more than 80% of the patients received the
analgesic therapy at least once a day, opioids offered benefit
to about 70% of the patients with advanced motoneuronal
disease [108, 109]. The treatment of spasticity by intrathecal
baclofen may also alleviate pain though this aspect was
rarely considered [110]. In addition, although riluzole is
actually indicated as the only available disease-modifying
medication and confers a little survival advantage, the effects
of symptomatic treatment on pain remain unclear [111].
Again, pain associated with ALS is believed to be largely due
to immobility. Physiotherapy, stretching, and range ofmotion
exercises used in combination with pharmacotherapies to
prevent contractures and reduce cramping and spasticity can
be effective for associated pain [107, 112].
5.5. Main Limitations of Present Studies and Future Directions.
ALS is a complex disorder where pain is currently considered
an important but not primary end point in current manage-
ment. Studies on pain frequency in ALS present the limits to
be conducted in single centers in small samples, to rarely have
a reliable control population, to be frequently retrospective,
and to use usually nonvalidated methods for pain evaluation
so the real impact of pain symptoms on the global burden of
the disease is still unknown. Neurophysiological examination
is limited to standard examination of sensory neurography,
and the few studies with neurophysiological techniques
exploring the nociceptive and nonnociceptive somatosensory
system were conducted in small cohorts of patients in dif-
ferent stages of the disease. Controlled randomized trials on
different pain killers are still lacking, and pain was considered
only in some studies focusing on the global management of
ALS.
Considering the impact of pain on the total outcome of
ALS, a systematic clinical approachwith specific scale for pain
features and invalidity should be used in patients who report
painful symptoms. A neurophysiological assessment of sen-
sory functions by means of somatosensory nociceptively
Behavioural Neurology 9
and nonnociceptively evoked responses might complete the
standard examination [98]. The effects of treatments on
pain should be considered, and specific, controlled trials are
needed.
Although Cannabis may potentially represent a thera-
peutic opportunity for many ALS symptoms including pain
[113, 114], evidence on its efficacy is presently scarce and based
only on one controlled study in a small patient group, with
negative results on pain release [115]. Angiotensin-converting
enzyme inhibitors may be also a potential approach to
neurodegenerative disorders and neuropathic pain [116]. In
addition, physical therapy and the other nonpharmacological
approachwould be finalized toward pain symptoms improve-
ment.
6. Other Rare Neurodegenerative Conditions
6.1. Spinocerebellar Ataxia (SCA). Among the neurodegener-
ative hereditary cerebellar ataxia conditions, there are at least
36 different forms of autosomal dominant cerebellar ataxia
(ADCA), 20 autosomal recessive cerebellar ataxia conditions,
two X-linked ataxia conditions, and several forms of ataxia
associated with mitochondrial defects [117].
A number of disease entities present with the ADCA
phenotype such as spinocerebellar ataxia (SCA) conditions,
dentatorubral-pallidoluysian atrophy, episodic ataxia, and
autosomal dominant spastic ataxia. SCA conditions can be
divided by themode of inheritance into autosomal dominant,
autosomal recessive, or sporadic conditions. There are many
types of spinocerebellar ataxia and about 30 different gene
mutations, 22 different genes, and 10 different gene loci have
been identified, but the numbers continue to grow [118–120].
The definition of SCA conditions, despite significant
progress in their understanding, is still imprecise, but the
development of genetic profiling has made genetic classi-
fications possible, which allows estimating the underlying
etiology in 60% of the patients [121]. SCA disorders are a
group of neurodegenerative disorders with clinical, genetic,
and neuropathological heterogeneity being characterized by
ataxia and other neurological signs such as oculomotor dis-
turbances, cognitive deficits, pyramidal and extrapyramidal
dysfunction, and bulbar, spinal, and peripheral nervous sys-
tem involvement [122]. The prevalence of ADCA conditions
is estimated to be around 3 in 100000, but it is highly variable
depending upon the geographical area [123, 124].
As compared with other neurodegenerative disorders
such as Parkinson’s disease, quantitative and validated assess-
ment tools are less developed [125]. The patients gener-
ally experience problems with mobility, usual activities,
pain/discomfort, depression/anxiety, and self-care. Different
population surveys have shown that 19 to 64% of patients
report pain as a problem in selected SCA conditions [126].
In the same study, multivariate analysis revealed three inde-
pendent predictors of subjective health status: ataxia severity,
extent of noncerebellar involvement, and the presence of
depressive syndrome. Although pain is not a primary inval-
idating factor in such patients, it may influence the quality
of life as part of depression-related symptoms cohort and
noncerebellar features.
In a recent systematic review reporting data from 1062
publications and 12141 patients with different neuromuscular
disorders, pain was found to be reported in 1 among 30 SCA
sufferers [127]. However, pain may often be underestimated
though it can be severe when related to dystonia. In SCA
conditions, pain can be misdiagnosed and mistreated but
successfully ameliorated by, for example, botulinum toxin
therapy [128].
There are currently no cures for SCA and treatments
(pharmacological therapy and physiotherapy) target the
symptoms such as pain, spasticity, tremor, stiffness, postural
balance, gait disabilities, sleep problems, and depression.
However, there are some very preliminary and nonvalidated
data suggesting the use of umbilical cord mesenchymal stem
cells in SCA [129].
6.2. Spinal Muscular Atrophy (SMA). Spinal muscular atro-
phy (SMA) is an autosomal, recessive, severe neuromuscular,
degenerative disease characterized by loss of alpha motor
neuron function in the spinal cord resulting in progressive
proximal symmetrical muscle weakness often greater in the
legs than in arms, atrophy, and paralysis and eventually
in impairment of respiration and dysphagia. SMA is the
second most common lethal, autosomal, recessive disorder
in Caucasians with an incidence of approximately 1/6000
and a carrier frequency of 1/50 [130]. The muscle weakness
can cause contracture formation, spinal deformity, limited
mobility, and activities of daily living and eventually cause
pain.
Engel et al. [131] found chronic pain in most patients
classified as “other MND” including the CMT disease,
all forms of spinal muscular atrophy, and many forms of
mitochondrial and congenital myopathies. Pain was most
frequently reported in the legswith amild intensity (1.3, range
0–6 on the 0–11 numerical scale) [131].
7. Conclusions
Neurodegenerative diseases represent a social, medical, and
economic problem and constitute a main field of interest
for neurologists. Pain may be one of the most debilitating
symptoms and a mode to express subjective discomfort and
sufferance. Motor and sensory deficit may directly cause pain
as in amyotrophic lateral sclerosis, Parkinson’s disease, spinal
cerebellar ataxia, and hereditary neuropathies where the sub-
jective expression may be limited by the motor impairment.
In demented patients, pain may be caused by different factors
as age-related muscle skeletal degeneration, immobility, or
neurodegeneration in brain areas involved in pain inhibition
though subjective sufferance manifestation may be limited
by cognitive impairment. The present review outlined a
general medical carelessness with regard to pain as attention
is especially pointed to the main illness symptoms. However,
in many conditions such as Parkinson’s disease, amyotrophic
lateral sclerosis, and chronic familiar polyneuropathy, pain
is largely represented among patients pending its specific
assessment. Even in Alzheimer’s disease, if special care is
provided and specific scales are used, pain appears not to
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be a secondary problem but instead it appears worthy of
full consideration. In rare conditions as Huntington’s disease,
pain expression may be also limited, and its causes would
be underestimated and neglected. As a consequence of the
scarce attention generally dedicated to pain, no controlled
trials and specific treatment guidelines are available, and pain
therapy is generally based on the symptomatic approach by
analgesics and anti-inflammatory drugs without a systematic
consideration of the causal mechanisms. Current evidences
about the relevance of pain in neurodegenerative disorders
indicate the opportunity of a full involvement of neurologists
in pain management taking into consideration its causes
and mechanisms giving special attention to predisposing
factors symptoms, employing and validating specific scales
performing the clinical and instrumental assessment of
sensory functions promoting therapeutic trials by means of
pharmacological and nonpharmacological approach. Con-
sidering the centrality of pain in individual suffering, the
question “Do you feel, or did he/she feel pain?” followed by a
careful observation and consideration of the contribution of
painful symptoms to the global burden of the disease should
be included in the routine assessment of neurodegenerative
diseases to finalize the best therapeutic choice.
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